NCT02393157 - Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell LymphomaPrimary Mediastinal B-cell LymphomaCD20+ Lymphoblastic LymphomaFollicular Lymphoma, Grade III

Interventions

DRUG

Obinutuzumab

Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.

DRUG

Liposomal ARA-C

Will be given intrathecally for both prophylaxis and treatment of CNS disease.

DRUG

Ifosfamide

Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.

DRUG

Carboplatin

Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.

DRUG

Etoposide

Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).

Trial Locations (1)

10595

RECRUITING

New York Medical College, Valhalla